Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Neratinib Efficacy and Circulating Tumor DNA Detection of
Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 1 pooled it
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.
- Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.Clinical drug investigation · 2019Pooled it
- Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Pathway activity profiling can predict neoadjuvant endocrine therapy response in HR+ HER2- postmenopausal early stage breast cancer.Breast cancer research : BCR · 2026Trial
- Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- Trial
- The molecular tumor burden index as a response evaluation criterion in breast cancer.Signal transduction and targeted therapy · 2021Trial
- Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer.Journal of geriatric oncology · 2021Trial
- Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.Gynecologic oncology · 2020Trial
- Efficacy and Determinants of Response to HER Kinase Inhibition inCancer discovery · 2020Trial
- Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.Cancer cell · 2019Trial
- Trial
- The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer.Molecular diagnosis & therapy · 2025Review
- Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.BMC cancer · 2025Article
- Silver Jubilee of HER2 targeting: a clinical success in breast cancer.Journal of the National Cancer Center · 2025Review
- A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.Scientific data · 2025Article
- HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.bioRxiv : the preprint server for biology · 2025Article
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring.Frontiers in oncology · 2025Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 15 institutions in 2 countries.
Cynthia X MaDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. cynthiaxma@wustl.edu rbose@wustl.edu mjellis@bcm.edu.
Ron BoseDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri. cynthiaxma@wustl.edu rbose@wustl.edu mjellis@bcm.edu.
Feng GaoDivision of Public Health Science, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Rachel A FreedmanMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Melinda L TelliDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Gretchen KimmickDepartment of Medicine, Duke Cancer Institute, Durham, North Carolina.
Eric WinerMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Michael NaughtonDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Matthew P GoetzMedical Oncology, Mayo Clinic, Rochester, Minnesota.
Christy RussellMedical Oncology, University of Southern California, Los Angeles, California.
Debu TripathyMedical Oncology, University of Southern California, Los Angeles, California.
Melody CobleighMedical Oncology, Rush University Medical Center, Chicago, Illinois.
Andres ForeroDepartment of Medicine, University of Alabama Birmingham, Birmingham, Alabama.
Timothy J PluardDepartment of Oncology-Hematology, St. Luke's Cancer Institute, Kansas City, Missouri.
Carey AndersDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Polly Ann NiravathLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Shana ThomasDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Jill AndersonDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Caroline BumbDivision of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri.
Kimberly C BanksGuardant Health Inc., Redwood City, California.
Richard B LanmanGuardant Health Inc., Redwood City, California.
Richard BrycePuma Biotechnology, Los Angeles, California.
Alshad S LalaniPuma Biotechnology, Los Angeles, California.
John PfeiferGenomic and Pathology Service, Washington University School of Medicine, St. Louis, Missouri.
Daniel F HayesDepartment of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan.
Mark PegramDepartment of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
Kimberly BlackwellDepartment of Medicine, Duke Cancer Institute, Durham, North Carolina.
Philippe L BedardMedical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Hussam Al-KatebGenomic and Pathology Service, Washington University School of Medicine, St. Louis, Missouri.
Matthew J C EllisLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. cynthiaxma@wustl.edu rbose@wustl.edu mjellis@bcm.edu.
Washington University in St. Louis · USBaylor College of Medicine · USDana-Farber Cancer Institute · USDuke Medical Center · USGuardant (United States) · USPuma Biotechnology (United States) · USStanford Medicine · USUniversity of Southern California · USMayo Clinic · USPrincess Margaret Cancer Centre · CARush University Medical Center · USSaint Luke's Health System · USUniversity of Alabama at Birmingham · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MNCI NIH HHS P30 CA016086NCI NIH HHS P30 CA091842
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedBreast NeoplasmsCirculating Tumor DNADisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedMutationNeoplasm MetastasisQuinolinesTreatment OutcomeCirculating Tumor DNAERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesneratinibQuinolines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.